Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Live attenuated vaccine for hepatitis A.

S M Feinstone, R J Daemer, I D Gust

    Developments in Biological Standardization
    |January 1, 1983
    PubMed
    Summary

    Developing a live, attenuated hepatitis A vaccine (HAV) is feasible. Serial passage of the HM-175 strain in tissue culture attenuated the virus, making it a promising candidate for active immunoprophylaxis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference.

    Biologicals : journal of the International Association of Biological Standardization·2010
    Same author

    Replicating viral vectors as HIV vaccines Summary Report from IAVI Sponsored Satellite Symposium, International AIDS Society Conference, July 22, 2007.

    Biologicals : journal of the International Association of Biological Standardization·2008
    Same author

    A global lab against influenza.

    Science (New York, N.Y.)·2001
    Same author

    Planning for the next pandemic of influenza.

    Reviews in medical virology·2001
    Same author

    Epidemiology of hepatitis B infection in the Western Pacific and South East Asia.

    Gut·1996
    Same author

    Immunisation against hepatitis B in Taiwan.

    Gut·1996

    Area of Science:

    • Virology
    • Vaccinology
    • Hepatitis Research

    Background:

    • Hepatitis B vaccine success spurs interest in Hepatitis A virus (HAV) vaccines.
    • HAV propagation in tissue culture and animal models simplifies vaccine development.
    • Both inactivated and live, attenuated HAV vaccines are potential candidates.

    Purpose of the Study:

    • To evaluate the feasibility of developing a live, attenuated Hepatitis A vaccine.
    • To assess the attenuation of the HM-175 HAV strain after serial passage in tissue culture.
    • To determine the safety and efficacy of the attenuated strain in a chimpanzee model.

    Main Methods:

    • The HM-175 HAV strain was serially passaged over 20 times in African green monkey kidney (AGMK) cells.
    • Parent strain and passaged virus (at passages 10 and 20) were tested for infectivity and virulence in chimpanzees.
    • Chimpanzee liver enzymes and viral antigen presence in biopsies and stool were monitored.

    Main Results:

    • The parent HAV strain caused liver damage in chimpanzees.
    • Tissue culture-passaged HAV remained infectious but did not induce hepatitis.
    • No significant viral antigen was detected in chimpanzee liver biopsies or stool post-infection.

    Conclusions:

    • Serial passage in tissue culture effectively attenuates the HM-175 HAV strain.
    • Attenuated HAV is a viable candidate for a live, attenuated vaccine.
    • This approach offers a promising strategy for hepatitis A immunoprophylaxis.

    Related Experiment Videos